| Name | Caspofungin Acetate |
| Description | Caspofungin Acetate (MK 0991) is the acetate salt of an antimycotic echinocandin lipopeptide, semisynthetically derived from a fermentation product of the fungus Glarea lozoyensis. This agent is active against Aspergillus and Candida species. |
| In vitro | Caspofungin acetate is the first in a new class of antifungals that inhibits the synthesis of beta (1, 3)-d-glucan, an essential component of the cell wall of filamentous fungi. Prior studies have shown in vitro activity of caspofungin acetate using the reference methods, broth microdilution or macrodilution, for antifungal susceptibility testing of Candida species established by the National Committee for Clinical Laboratory Standards 1997 guidelines against a variety of Candida species including Candida krusei. Although caspofungin acetate is only Food and Drug Administration-approved for the treatment of aspergillosis, there is information showing that many Candida species are susceptible. The minimal inhibitory concentration for 90% inhibition of Candida species by caspofungin acetate are as follows:C. albicans 0.5 μg/mL (range, 0.25-0.5), C. glabrata 1.0 μg/mL (range, 0.25-2.0), C. tropicalis 1.0 μg/mL (range, 0.25-1.0), C. parapsilosis 0.5 μg/mL (range, 0.25-1.0), and C. krusei 2.0 μg/mL (range, 0.5-2.0) |
| In vivo | Mice injected with caspofungin at vitreal concentrations from 0.41 to 4.1 μM cause no significant alterations in their ERG waveforms and their retinas have no detectable morphologic changes or loss of cells. At the vitreal concentration of 41 μM, caspofungin reduces the amplitudes of the a-waves, b-waves, and scotopic threshold responses of the ERG and also produces a decrease in the number of cells in the ganglion cell layer[4]. Caspofungin (8 mg/kg) or amphotericin B at 1 mg/kg given i.p. once daily for 7 days beginning at 30 h after infection resulted in 100% survival through day 28 relative to vehicle control treatment, which results in 100% mortality by day 11 after infectious challenge. Caspofungin reduces recovery of viable Candida from kidney and brain tissues compared to vehicle control treatment on day 5, when control burden peaked. Caspofungin-treated mice dosed with 2 mg/kg or greater have significantly lower brain burden than amphotericin-B-treated mice at day 5. Amphotericin B and caspofungin treatment reduce kidney fungal burden by 1.7 log CFU/g and 2.46 to 3.64 log CFU/g, respectively[5]. |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 83.3 mg/mL (68.65 mM)
H2O : 100 mg/mL (82.41 mM)
|
| Keywords | fungal cell wall | inhibit | MK-0991 diacetate | Caspofungin Acetate | L743873 | MK-0991 | Fungal | Inhibitor | L-743872 | antifungal | Caspofungin diacetate | MK0991 | Antibiotic | L-743873 | L-743872 diacetate | L743872 |
| Inhibitors Related | Neomycin sulfate | Dehydroacetic acid sodium | Ampicillin sodium | Kanamycin sulfate | G-418 disulfate | Sulfamethoxazole sodium | Metronidazole | Doxycycline | Geraniol | EDTA copper(II) disodium salt |
| Related Compound Libraries | Cyclic Peptide Library | Bioactive Compound Library | Anti-Fungal Compound Library | Antibiotics Library | Drug Repurposing Compound Library | NO PAINS Compound Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Anti-Infection Compound Library | Anti-COVID-19 Compound Library |
United States
